Pazopanib in metastatic multiply treated progressive gastrointestinal stromal tumors: feasible and efficacious

BACKGROUND: A median progression free survival (PFS) of 18–20 months and median overall survival (OS) of 51–57 months can be achieved with the use of imatinib, in metastatic or advanced gastrointestinal stromal tumor (GIST). Sunitinib and regorafenib are approved options for patients progressing on...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:J Gastrointest Oncol
Main Authors: Ramaswamy, Anant, Pande, Nikhil, Shetty, Omshree, Shetty, Nitin, Gupta, Sudeep, Ostwal, Vikas
Format: Artigo
Sprog:Inglês
Udgivet: AME Publishing Company 2016
Fag:
Original Article
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4963378/
https://ncbi.nlm.nih.gov/pubmed/27563456
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/jgo.2016.03.06
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker